Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
|Articles|November 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 11
- Volume 5
- Issue 11
'Cancer Rates and Risks' Available
BETHESDA, Md--The National Cancer Institute has released the latest edition of Cancer Rates and Risks, a 205-page reference book with cancer statistics and brief chapters by NCI experts, written in lay language, on known cancer risk factors. Single copies are available free through the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
Advertisement
BETHESDA, Md--The National Cancer Institute has released the latest edition of Cancer Rates and Risks, a 205-page reference book with cancer statistics and brief chapters by NCI experts, written in lay language, on known cancer risk factors. Single copies are available free through the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
Articles in this issue
almost 30 years ago
Factor Analysis of New Symptom Scale in Breast Cancer Finds Six Clustersabout 30 years ago
AIDS Funding Increased for Fiscal '97about 30 years ago
New Breast Cancer Patient Resource Is Availableabout 30 years ago
Short-Term Metronidazole not Linked to Cancerabout 30 years ago
Various Capitation Models Are Available for Oncology Networksabout 30 years ago
NCI Urges full Disclosure of Cigarette Contentsabout 30 years ago
Antifungal Resistance on the Increaseabout 30 years ago
Fentanyl Patch Useful Alternative in Cancer Pain Patientsabout 30 years ago
Analysis of Microvessel Density Predicts Extraprostatic SpreadAdvertisement
Related to this article
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
4
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
5